REPORT ID 3396

EMEA (Europe, Middle East and Africa) Granulocyte Macrophage Colony Stimulating Factor Market Report 2017

Publish Date
13-Dec-17
Pages
101
Format
Electronic (PDF)

In this report, the EMEA Granulocyte Macrophage Colony Stimulating Factor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Granulocyte Macrophage Colony Stimulating Factor for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Granulocyte Macrophage Colony Stimulating Factor market competition by top manufacturers/players, with Granulocyte Macrophage Colony Stimulating Factor sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Aduro BioTech Inc
    Amgen Inc
    BriaCell Therapeutics Corp
    Cold Genesys Inc
    GlaxoSmithKline Plc
    Humanigen Inc
    Mologen AG
    Morphotek Inc
    Sillajen Biotherapeutics
    Takeda Pharmaceutical Co Ltd

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    CG-0070
    Gimsilumab
    GSK-3196165
    Lenzilumab
    MGN-1601
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Solid Tumor
    Lymphoma
    Kidney Cancer
    Lung Disease
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Granulocyte Macrophage Colony Stimulating Factor Market Report 2017
1 Granulocyte Macrophage Colony Stimulating Factor Overview
    1.1 Product Overview and Scope of Granulocyte Macrophage Colony Stimulating Factor
    1.2 Classification of Granulocyte Macrophage Colony Stimulating Factor
        1.2.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Granulocyte Macrophage Colony Stimulating Factor Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 CG-0070
        1.2.4 Gimsilumab
        1.2.5 GSK-3196165
        1.2.6 Lenzilumab
        1.2.7 MGN-1601
        1.2.8 Others
    1.3 EMEA Granulocyte Macrophage Colony Stimulating Factor Market by Application/End Users
        1.3.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Solid Tumor
        1.3.3 Lymphoma
        1.3.4 Kidney Cancer
        1.3.5 Lung Disease
        1.3.6 Others
    1.4 EMEA Granulocyte Macrophage Colony Stimulating Factor Market by Region
        1.4.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Granulocyte Macrophage Colony Stimulating Factor (2012-2022)
        1.5.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Granulocyte Macrophage Colony Stimulating Factor Revenue and Growth Rate (2012-2022)

2 EMEA Granulocyte Macrophage Colony Stimulating Factor Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Market Competition by Players/Manufacturers
        2.1.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Granulocyte Macrophage Colony Stimulating Factor Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Granulocyte Macrophage Colony Stimulating Factor Sale Price by Players (2012-2017)
    2.2 EMEA Granulocyte Macrophage Colony Stimulating Factor (Volume and Value) by Type/Product Category
        2.2.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Granulocyte Macrophage Colony Stimulating Factor Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Granulocyte Macrophage Colony Stimulating Factor Sale Price by Type (2012-2017)
    2.3 EMEA Granulocyte Macrophage Colony Stimulating Factor (Volume) by Application
    2.4 EMEA Granulocyte Macrophage Colony Stimulating Factor (Volume and Value) by Region
        2.4.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Granulocyte Macrophage Colony Stimulating Factor Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales Price by Region (2012-2017)

3 Europe Granulocyte Macrophage Colony Stimulating Factor (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Granulocyte Macrophage Colony Stimulating Factor Sales and Value (2012-2017)
        3.1.1 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Granulocyte Macrophage Colony Stimulating Factor Revenue and Growth Rate (2012-2017)
    3.2 Europe Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Type
    3.3 Europe Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Application
    3.4 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Countries (2012-2017)
        3.4.2 Europe Granulocyte Macrophage Colony Stimulating Factor Revenue by Countries (2012-2017)
        3.4.3 Germany Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        3.4.4 France Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        3.4.5 UK Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        3.4.6 Russia Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        3.4.7 Italy Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)

4 Middle East Granulocyte Macrophage Colony Stimulating Factor (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Granulocyte Macrophage Colony Stimulating Factor Sales and Value (2012-2017)
        4.1.1 Middle East Granulocyte Macrophage Colony Stimulating Factor Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Granulocyte Macrophage Colony Stimulating Factor Revenue and Growth Rate (2012-2017)
    4.2 Middle East Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Type
    4.3 Middle East Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Application
    4.4 Middle East Granulocyte Macrophage Colony Stimulating Factor Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Granulocyte Macrophage Colony Stimulating Factor Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        4.4.4 Israel Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        4.4.5 UAE Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        4.4.6 Iran Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)

5 Africa Granulocyte Macrophage Colony Stimulating Factor (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Granulocyte Macrophage Colony Stimulating Factor Sales and Value (2012-2017)
        5.1.1 Africa Granulocyte Macrophage Colony Stimulating Factor Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Granulocyte Macrophage Colony Stimulating Factor Revenue and Growth Rate (2012-2017)
    5.2 Africa Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Type
    5.3 Africa Granulocyte Macrophage Colony Stimulating Factor Sales and Market Share by Application
    5.4 Africa Granulocyte Macrophage Colony Stimulating Factor Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Countries (2012-2017)
        5.4.2 Africa Granulocyte Macrophage Colony Stimulating Factor Revenue by Countries (2012-2017)
        5.4.3 South Africa Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2012-2017)

6 EMEA Granulocyte Macrophage Colony Stimulating Factor Manufacturers/Players Profiles and Sales Data
    6.1 Aduro BioTech Inc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Amgen Inc
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 BriaCell Therapeutics Corp
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Cold Genesys Inc
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 GlaxoSmithKline Plc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Humanigen Inc
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Mologen AG
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Morphotek Inc
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Sillajen Biotherapeutics
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Takeda Pharmaceutical Co Ltd
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Granulocyte Macrophage Colony Stimulating Factor Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Granulocyte Macrophage Colony Stimulating Factor Manufacturing Cost Analysis
    7.1 Granulocyte Macrophage Colony Stimulating Factor Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Granulocyte Macrophage Colony Stimulating Factor

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Granulocyte Macrophage Colony Stimulating Factor Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Granulocyte Macrophage Colony Stimulating Factor Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Granulocyte Macrophage Colony Stimulating Factor Market Forecast (2017-2022)
    11.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Granulocyte Macrophage Colony Stimulating Factor Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Granulocyte Macrophage Colony Stimulating Factor Price and Trend Forecast (2017-2022)
    11.2 EMEA Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Growth Rate Forecast by Region (2017-2